��������

Hadrien Bouchez is currently the director at Ermium Therapeutics. Prior to this, they were with Kurma Partners and before that, Servier. Bouchez was an analyst at Servier, where they worked on drug acquisition and in-licensing from January 2013 to December 2013. Hadrien was also a research scientist at Université de Genève from January 2011 to December 2011, where they worked on new strategies to enhance the immunogenicity of a DNA vaccine against tuberculosis.

Hadrien Bouchez has a certificate in corporate finance from HEC Paris, an advanced master's degree in entrepreneurship from ESSEC Business School, and a Pharm.D from the University of Lille 1 Sciences and Technology. Hadrien is also certified by the Autorité des marchés financiers (AMF) in France.